| Ge, Junbo |
NCT03008083: Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation |
|
|
| Recruiting | 4 | 2446 | RoW | 3 months DAPT, Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), 12 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention | 12/20 | 10/22 | | |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia |
|
|
| Recruiting | 3 | 240 | RoW | AK102, Placebo | Akeso | Hyperlipidemia | 06/22 | 12/22 | | |
| Active, not recruiting | 2 | 100 | RoW | Pirfenidone Oral Capsule, Placebo Oral Capsule | Shanghai Zhongshan Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Myocardial Fibrosis | 05/24 | 06/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT03466918: China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population |
|
|
| Active, not recruiting | N/A | 58 | RoW | SAPIEN 3 THV with the Commander delivery system | Edwards Lifesciences | Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation | 07/19 | 09/25 | | |
NCT04582877: Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial |
|
|
| Completed | N/A | 300 | RoW | FFR measurement | Zurich Medical Inc. | Myocardial Ischemia | 11/23 | 04/24 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT04414878: VitaFlowâ„¢ II Transcatheter Aortic Valve System Pre-market Trial |
|
|
| Recruiting | N/A | 145 | RoW | VitaFlowâ„¢ II Transcatheter Aortic Valve System | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Aortic Stenosis | 01/22 | 01/27 | | |
NCT06110988: A Clinical Study for the Pan-vascular Interventional Robotic System |
|
|
| Not yet recruiting | N/A | 5 | RoW | Pan-vascular interventional robotic system | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention, Pan-vascular Interventional Robotic System | 09/24 | 09/24 | | |
NCT03736226: A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China |
|
|
| Active, not recruiting | N/A | 2000 | RoW | SYNERGYTM Stent System | Boston Scientific Corporation | Cardiovascular Diseases | 08/24 | 03/28 | | |
NCT06502938: A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional Surgery |
|
|
| Not yet recruiting | N/A | 159 | RoW | Pan-vascular interventional robotic system, Traditional artificial percutaneous coronary intervention | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention | 07/25 | 12/25 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT06032572: Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) |
|
|
| Not yet recruiting | N/A | 204 | RoW | VRS100 robotic-assisted PCI, Manual PCI | Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Shanghai Zhongshan Hospital, West China Hospital, Shenzhen People's Hospital | Coronary Artery Disease, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Arteriosclerosis, Vascular Disease Occlusive | 08/24 | 08/24 | | |
VITAL, NCT05813704: Coronary Crossing System in Patients With Coronary Chronic Total Occlusions |
|
|
| Recruiting | N/A | 156 | RoW | Coronary Crossing System of Shanghai MicroPort Rhythm | Shanghai MicroPort Rhythm MedTech Co., Ltd., Shanghai Zhongshan Hospital, Xiamen Cardiovascular Hospital, Xiamen University, Shanghai Baoshan District Wusong Central Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Wenzhou Medical University, Tianjin First Central Hospital, The Affiliated Hospital Of Southwest Medical University, Hebei General Hospital, West China Hospital, First Affiliated Hospital of Army Medical University, PLA, Lanzhou University First Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Chronic Total Occlusion of Coronary Artery | 04/25 | 05/25 | | |
NCT05947448: Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study |
|
|
| Recruiting | N/A | 1215 | RoW | Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table | Hasten Biopharmaceutical Co., Ltd. | Essential Hypertension | 06/25 | 12/25 | | |
| Wang, Zhen Jun |
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants |
|
|
| Completed | 3 | 241 | RoW | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd | Acute Migraine | 02/24 | 02/24 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
NCT06295432: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) |
|
|
| Recruiting | 2 | 90 | RoW | DZD9008+AZD4205, Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT06139536: Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients |
|
|
| Recruiting | 1 | 210 | RoW | BAT4706 Injection, Fc-glycosylated recombinant fully humanized anti-CTLA-4 monoclonal antibody injection, BAT1308 Injection, Recombinant humanized anti PD-1 monoclonal antibody injection | Bio-Thera Solutions | Advanced Solid Tumor | 12/25 | 02/26 | | |
NCT05982080: A Study to Investigate FP002 in Subjects With Advanced Malignancies |
|
|
| Recruiting | 1 | 27 | RoW | FP002 Injection | Guangdong Fapon Biopharma Inc. | Advanced Solid Tumor | 04/25 | 07/26 | | |
